Selective NLRP3 Inflammasome Inhibitors for Inflammaging

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Aging frailty and inflammaging are characterized by chronic inflammation mediated through the NLRP3 inflammasome, leading to a range of age-related diseases and immune dysregulation, for which effective therapeutic targets are lacking.

Innovation Solution

Development of compounds that inhibit the NLRP3 inflammasome, including specific chemical structures represented by Formulas I, II, III, IV, and VI, and their pharmaceutically acceptable salts, which can be administered to inhibit NLRP3 inflammasome activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If NLRP3 inflammasome is inhibited to treat inflammation and age-related diseases, then therapeutic efficacy is improved, but potential off-target effects and immune suppression may occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidoff-target effects and immune suppression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs selective inhibition of NLRP3 inflammasome specifically in inflammatory and age-related disease contexts, rather than complete suppression. The compounds are designed to target NLRP3 in specific tissue environments (e.g., inflamed tissues, aging organs) while preserving normal immune function in healthy tissues, thereby achieving local therapeutic effects without systemic immune suppression

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent modulates NLRP3 inflammasome activity rather than completely blocking it. By adjusting the degree of inhibition through controlled dosing and selective compound design, the therapy achieves sufficient suppression of pathological inflammation while maintaining baseline immune function, thus balancing efficacy with safety

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If broad-spectrum NLRP3 inhibition is used to treat multiple age-related diseases, then versatility of treatment is improved, but risk of adverse effects increases

Engineering Contradiction:

Improvetreatment versatilityVSAvoidadverse effects

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent develops NLRP3 inhibitors with broad applicability across multiple age-related conditions (inflammaging, neurodegenerative diseases, cardiovascular diseases, metabolic disorders) using a unified mechanism of action. The same compound class can be adapted for different indications by adjusting dosage and administration protocols, achieving versatile treatment without requiring disease-specific modifications to the core inhibitor

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent addresses the risk of adverse effects from broad-spectrum inhibition by leveraging the natural redundancy in inflammatory pathways. While NLRP3 inhibition may affect multiple systems, the body's alternative inflammatory mechanisms compensate for NLRP3 suppression, converting the potential harm of broad inhibition into a beneficial therapeutic effect across multiple disease types

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12435043B2Inhibitors of NLRP3 inflammasome

Publication Date: 2025.10.07 BIOAGE LABS INC

AI summary

The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging; wherein the inhibitors of NLRP3 inflammasomes are compounds of Formula VII:or a pharmaceutically acceptable salt thereof.